Call Now : (630)372-1100
Call Now : (630) 372-1100
Check out the Suburban Orthopaedics Blog! Click here to read more
Create Your Account for our New Patient Portal
The cervical spine has discs between each bone that provide cushioning for movements and body loads. The discs and bones in a healthy neck allow bending from side to side and front to back, and turning left to right. Disc problems can start from over-use, an accident, or just the wear and tear of daily life. Degenerative changes in the discs may result in damage that can cause pain. When a disc degenerates it can have tears or cracks that lose water, which cause it to become thinner and provide less padding to absorb movement. Degenerated discs can also bulge (herniate) and pinch the spinal cord or nerves, which causes loss of feeling, weakness, pain, or tingling down the arms and hands.
Before artificial discs were available, patients would often receive an Anterior Cervical Discectomy and Fusion (ACDF) procedure to alleviate the pain from a herniated disc. In a fusion surgery, the disc is removed and either a bone spacer or a plastic implant will be placed in the disc space to restore disc height and remove pressure on the pinched nerves or spinal cord. A metal plate and screws can be placed on the front of the neck to hold the implant in place. The result of this procedure will be a segment that no longer moves, or is “fused”. The potential downside of a fusion procedure, in addition to the loss of motion, is that it can create additional stress on the spinal levels above and below it. This can cause degeneration at those levels and potentially result in another future surgery.
An artificial disc like Mobi-C is an option instead of a fusion that will also be placed inside the disc space to restore height and remove pressure on the pinched nerves. However, the Mobi-C device is designed to allow the neck to maintain normal motion and potentially prevent the adjacent levels from degenerating, possibly preventing future surgeries.
In the U.S. the prevalence of symptomatic cervical disc disease was estimated at 1.1 million people in 2012. There are over 266,000 anterior cervical procedures performed each year. It is estimated that 30,000 of the 266,000 anterior cervical procedures in 2012 were artificial disc. Cervical disc replacement procedures are anticipated to experience rapid growth in the near future. Growth in the next 5 years will be due to multiple factors:
The Mobi-C cervical disc is one of the most widely used cervical discs in the world. First implanted in Orleans, France in November 2004, Mobi-C has been implanted in more than 17,000 spinal levels in 25 countries.
Mobi-C entered an FDA clinical trial in 2006, in which 647 levels of Mobi-C were implanted. A total of 599 patients were involved in the clinical trial at 24 study centers across the U.S. This represents the largest clinical trial ever conducted in the U.S. for cervical disc replacement. Mobi-C received FDA approval in August of 2013, making it the first cervical disc with both one and two-level indications.
Mobi-C is made with two Cobalt Chromium alloy endplates that are plasma sprayed with Titanium and coated with hydroxyapatite, and an Ultra High Molecular Weight Polyethylene plastic insert (UHMWPE). These are proven materials that have been used in orthopedic applications for over 60 years.
Mobi-C is intended for adult patients (skeletally mature) with arm pain and/or neurological symptoms (such as weakness or numbness) with or without neck pain at one or two adjacent levels from C3 – C7 in the cervical spine. Patients should have failed non-surgical care (such as physical therapy or medications) for at least 6 weeks, or shown signs of progressively worsening symptoms. Disc damage needs to be confirmed by a doctor’s review of CT, MRI, or x-ray images. A doctor should always be consulted for proper indications and use of Mobi-C.
In the one-level study, Mobi-C demonstrated non-inferiority to ACDF as reflected in the primary composite endpoint. In the two-level study Mobi-C demonstrated SUPERIORITY to ACDF in the primary composite endpoint. Key results from the two-level study include:
– 2.9% of Mobi-C patients compared to 18.1% of ACDF patients at the inferior adjacent level
– 13.1% of Mobi-C patients compared to 33.3% of ACDF patients at the superior adjacent level
For detailed clinical results, see the Mobi-C Summary of Safety and Effectiveness document (SSED) online at www.ldr.com or >www.fda.gov or visit www.cervicaldisc.com
To request an appointment please call us at (630) 372-1100 or fill out the form below and a member of our staff will contact you shortly: